comparemela.com
Home
Live Updates
FDA Approves Polatuzumab Vedotin Plus R-CHP for Previously Untreated DLBCL : comparemela.com
FDA Approves Polatuzumab Vedotin Plus R-CHP for Previously Untreated DLBCL
The FDA has approved polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for certain patients with treatment-naive diffuse large B-cell lymphoma.
Related Keywords
Roche Polivy ,
Oncologic Drugs Advisory Committee ,
International Prognostic Index ,
Youtube ,
Meeting Of The Oncologic Drugs Advisory Committee ,
Drugs Advisory Committee ,
Pacific Lymphoma Conference ,
Polatuzumab Vedotin Piiq ,
Diffuse Largeb Cell Lymphoma ,
Dlbcl ,
comparemela.com © 2020. All Rights Reserved.